Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Liabilities and Shareholders Equity (2021 - 2025)

Krystal Biotech's Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $1.3 billion for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 26.33% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $4.8 billion, up 25.66%, while the annual FY2025 figure was $1.3 billion, 26.33% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.3 billion at Krystal Biotech, up from $1.2 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.3 billion in Q4 2025 and bottomed at $443.0 million in Q1 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $737.2 million (2023), against an average of $786.9 million.
  • The largest annual shift saw Liabilities and Shareholders Equity fell 13.78% in 2023 before it soared 60.44% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $626.3 million in 2021, then decreased by 10.83% to $558.4 million in 2022, then soared by 46.54% to $818.4 million in 2023, then grew by 29.02% to $1.1 billion in 2024, then grew by 26.33% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Liabilities and Shareholders Equity are $1.3 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).